



Audited Financial Results for the year ended December 31, 2011

Rs. in Lakhs

Sr. No	Particulars	Quarter ended (Unaudited)			Year ended (Audited)	Previous Period (Audited)
		December 31, 2011 (Refer Note 6 below)	September 30, 2011	November 30, 2010	December 31, 2011	December 1, 2009 to December 31, 2010
1	Net Sales/ Income from Operations					
	(a) Gross Sales	388,68	402,16	270,38	1463,75	995,98
	Less : Excise Duty	5,08	5,27	1,85	18,18	6,10
	Net Sales	383,60	396,89	268,53	1445,57	989,88
	(b) Other Operating Income	2,70	13,61	8,93	31,91	29,07
2	Expenditure					
	(a) (Increase)/ Decrease in Stock in Trade & Work in Progress	(86,44)	23,34	34,97	(73,64)	(25,08)
	(b) Consumption of Raw Materials	44,07	17,50	11,03	123,07	44,19
	(c) Purchase of Traded Goods	269,00	187,75	121,60	798,72	628,20
	(d) Employee Cost	37,60	47,89	28,74	167,35	111,20
	(e) Depreciation/ Amortisation	4,73	3,79	3,16	15,00	11,25
	(f) Other Expenditure	66,87	70,42	41,68	286,13	161,93
	(g) Total Expenditure	335,83	350,69	241,18	1316,63	931,69
3	Profit from Operations before other Income and Interest (1-2)	50,47	59,81	36,28	160,85	87,26
4	Other Income	5,45	4,88	2,05	19,33	6,93
5	Profit Before Interest (3+4)	55,92	64,69	38,33	180,18	94,19
6	Interest	1	-	-	3	4
7	Profit Before Tax	55,91	64,69	38,33	180,15	94,15
8	Tax Expense (including current tax, deferred tax and prior period adjustments for the period)	19,03	21,06	12,80	59,76	33,21
9	Net Profit for the period	36,88	43,63	25,53	120,39	60,94
10	Paid-up Equity Share Capital (Face Value of the share - Rs 10/-)	21,25	21,25	13,68	21,25	13,68
11	Reserves excluding revaluation reserves (as per last audited Balance Sheet)				522,89	291,71
12	Basic EPS and Diluted EPS for the periods (not annualised), year to date (not annualised) and for the previous period - Rs.	17.36	20.53	18.67	56.66	44.56
13	Public shareholding					
	Number of Shares	53,15,254	53,15,254	42,47,056	53,15,254	42,47,056
	Percentage of Shareholding	25.01%	25.01%	31.06%	25.01%	31.06%
14	Promoters and promoter group shareholding					
	(a) Pledged/ Encumbered :					
	Number of Shares	-	-	-	-	-
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
	Percentage of Shares (as a % of the total share capital of the company)	-	-	-	-	-
	(b) Non - encumbered :					
	Number of Shares	159,34,048	159,34,048	94,28,184	159,34,048	94,28,184
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%
	Percentage of Shares (as a % of the total share capital of the company)	74.99%	74.99%	68.94%	74.99%	68.94%

Notes :

1. The results for the quarter and year ended December 31, 2011 have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on February 28, 2012.
2. The Company changed its accounting year from year ended November 30 to year ended December 31 from the previous financial year onwards. Accordingly the result for the current quarter, being the fourth quarter of the current year, is for three months ended December 31, 2011 and the result of the corresponding fourth quarter of the previous period is for three months ended November 30, 2010.
Further the result for the current year is for twelve months ended December 31, 2011 and for the previous year is for a period of 13 months from December 1, 2009 to December 31, 2010.
3. (a) Erstwhile Solvay Pharma India Limited (hereinafter referred to as "Solvay Pharma") has merged with Abbott India Limited (hereinafter referred to as "Company") on August 10, 2011 ('Effective Date') according to the Scheme of Amalgamation ('Scheme') sanctioned by the Hon'ble High Court of Bombay. The swap ratio for the merger was 2:3 i.e. every two shares of Solvay Pharma entitled their holder's to three shares of the Company. The shares have been allotted on September 7, 2011 ('Date of Allotment') and the fractional entitlement of shares (equivalent to 497 shares) was paid in cash with reference to the price prevailing on Date of Allotment.
(b) The amalgamation has been accounted for under the "pooling of interests" method as prescribed by Accounting Standard 14 (AS 14) "Accounting for Amalgamations". Accordingly, the assets, liabilities and reserves of Solvay Pharma as at December 31, 2010 have been taken over at their book values after adjusting for
(i) the financial effect of conflicting accounting policies between the Company and Solvay Pharma
(ii) the additional share capital allotted by the Company (over the share capital of Solvay Pharma) and cash paid for the fractional shares.
(c) Under the Scheme, the amalgamation has taken place with effect from January 1, 2011 ('The Appointed Date'). Accordingly the above results for the quarter and year ended December 31, 2011 include the results of Solvay Pharma. The results for the previous quarter ended November 30, 2010 and 13 months ended December 31, 2010 are for Abbott India Limited before merger with Solvay Pharma.
(d) As on December 31, 2011, certain assets, liabilities and arrangements of Solvay Pharma are in the process of getting transferred to the Company.
4. In view of the change of accounting year referred to in note 2 above and the amalgamation referred to in note 3 above, the results for the quarter and year ended December 31, 2011 are not comparable to those of the corresponding previous periods.
5. The audited statement of assets and liabilities as on December 31, 2011 :

Particulars	As at December 31, 2011 (Audited) Rs in Lakhs	As at December 31, 2010 (Audited) Rs in Lakhs
Shareholders Funds		
(a) Capital	21,25	13,68
(b) Reserves and Surplus	522,89	291,71
	544,14	305,39
Deferred Tax Liability (Net)	-	18
Total	544,14	305,57
Fixed Assets	81,01	50,57
Deferred Tax Asset (Net)	6,20	-
Current Assets, Loans and Advances		
(a) Inventories	254,90	128,59
(b) Sundry Debtors	132,61	65,28
(c) Cash and Bank Balances	258,95	188,51
(d) Other Current Assets	4,63	1,20
(e) Loans and Advances	57,60	19,28
	708,69	402,86
Less : Current Liabilities and Provisions		
(a) Liabilities	160,42	97,96
(b) Provisions	91,34	49,90
	251,76	147,86
Net Current Assets	456,93	255,00
Total	544,14	305,57

6. The figures of quarter ended December 31, 2011 are the balancing figures between audited figures in respect of the full financial year up to December 31, 2011 and the unaudited published year-to-date figures up to the third quarter of the current financial year.

7. The Company continues to make strategic investments for expanding its field force and improve market coverage. The Company also continues to increase advertisement & promotional efforts to capture market share and increase brand equity & patient/ customer awareness. These initiatives are impacting the near term profitability. Further, the other expenses for the year ended December 31, 2011 also includes integration & amalgamation expenses and stamp duty.
8. The Company (including Solvay Pharma) operates in one reportable business segment i.e. "Pharmaceuticals" and one reportable geographical segment i.e. "Within India".
9. There was no investor complaint pending at the beginning of the quarter. The Company received 4 complaints from the investors. All complaints have been resolved and disposed off during the quarter. There was no complaint lying unresolved at the end of the quarter.
10. The Board of Directors at their meeting held on February 28, 2012 have recommended a dividend for 2011 of Rs. 17 per equity share (nominal value Rs 10/- per equity share)
11. Figures for the previous period have been regrouped and/or reclassified wherever considered necessary.

Abbott India Limited



Vivek Mohan
Managing Director

Mumbai
February 28, 2012

MS



By Hand

Bombay Stock Exchange Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

February 28, 2012
Scrip Code No. 500488

Dear Sirs,

Please note that pursuant to clause 20 (a) of the Listing Agreement, the Board has recommended a dividend of Rs 17.00/- per share on 2, 12, 49,302, equity shares of Rs 10/- each at the said meeting, subject to approval of the shareholders at the Annual General Meeting scheduled to be held on May 14, 2012.

Further the details required under clause 20 (b) are as under:

Rs Lakhs

	Year ended December 31, 2011	Thirteen months ended December 31, 2010
Total turnover	1445,57.29	989,88.08
Gross profit	597,42.75	342,57.34
Provision for Deprecation	14,99.53	11,25.03
Tax Provisions	59,76.53	33,20.98
Net profits	120,39.30	60,93.52
Amount appropriated from Reserves capital Profits Accumulated profits	-	-
Capital Profits	-	-
Accumulated profits past years or other special source to provide wholly or partly for the dividend	263,44.69	235,71.43

Thanking you,

Yours faithfully
Abbott India Limited

Krupa Anandpara
Company Secretary